OpenURL Connection Search

Select item for more details and to access through your institution.

Bleomycin.
Published in:
Annals of Internal Medicine, 1979, v. 90, n. 6, p. 945, doi. 10.7326/0003-4819-90-6-945
By:
- Bennett, John M.;
- Reich, Steven D.
Publication type:
Article
Initial clinical trials of the subrenal capsule assay as a predictor of tumor response to chemotherapy.
Published in:
1983
By:
- Griffin, Thomas W.;
- Bogden, Arthur E.;
- Reich, Steven D.;
- Antonelli, Donna;
- Hunter, Richard E.;
- Ward, Allen;
- Yu, Dinah T.;
- Greene, Harry L.;
- Costanza, Mary E.;
- Griffin, T W;
- Bogden, A E;
- Reich, S D;
- Antonelli, D;
- Hunter, R E;
- Ward, A;
- Yu, D T;
- Greene, H L;
- Costanza, M E
Publication type:
journal article
A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma ( NPI-0052-107): final study results.
Published in:
British Journal of Haematology, 2018, v. 180, n. 1, p. 41, doi. 10.1111/bjh.14987
By:
- Spencer, Andrew;
- Harrison, Simon;
- Zonder, Jeffrey;
- Badros, Ashraf;
- Laubach, Jacob;
- Bergin, Krystal;
- Khot, Amit;
- Zimmerman, Todd;
- Chauhan, Dharminder;
- Levin, Nancy;
- MacLaren, Ann;
- Reich, Steven D.;
- Trikha, Mohit;
- Richardson, Paul
Publication type:
Article
Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients.
Published in:
British Journal of Haematology, 2016, v. 174, n. 5, p. 711, doi. 10.1111/bjh.14113
By:
- Levin, Nancy;
- Spencer, Andrew;
- Harrison, Simon J.;
- Chauhan, Dharminder;
- Burrows, Francis J.;
- Anderson, Kenneth C.;
- Reich, Steven D.;
- Richardson, Paul G.;
- Trikha, Mohit
Publication type:
Article
COMMENTS AND CORRECTIONS.
Published in:
Annals of Internal Medicine, 1977, v. 86, n. 5, p. 652
By:
- Bohorfoush, J.G.;
- Crout, J. Richard;
- Napodano, Rudolph J.;
- Mitchell, Frank;
- Stross, Jeoffrey K.;
- Willis III, Park W.;
- Shapiro, Desmond J.;
- Adelman, Raymond D.;
- Weinrauch, L.A.;
- Healy, R.W.;
- Leland Jr., O.S.;
- Goldstein, H.H.;
- Kassissieh, S.D.;
- Libertino, J.A.;
- Takacs, F.J.;
- D'Elia, J.A.;
- Greco, F. Anthony;
- Oldham, Robert K.;
- Reich, Steven D.
Publication type:
Article
A randomized phase 1 pharmacokinetic trial comparing the potential biosimilar PF-05280014 with trastuzumab in healthy volunteers ( REFLECTIONS B327-01).
Published in:
British Journal of Clinical Pharmacology, 2014, v. 78, n. 6, p. 1281, doi. 10.1111/bcp.12464
By:
- Yin, Donghua;
- Barker, Kerry B.;
- Li, Ruifeng;
- Meng, Xu;
- Reich, Steven D.;
- Ricart, Alejandro D.;
- Rudin, Dan;
- Taylor, Carrie T.;
- Zacharchuk, Charles M.;
- Hansson, Arne G.
Publication type:
Article

Found: 6

Bleomycin.

Initial clinical trials of the subrenal capsule assay as a predictor of tumor response to chemotherapy.

A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma ( NPI-0052-107): final study results.

Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients.

COMMENTS AND CORRECTIONS.

A randomized phase 1 pharmacokinetic trial comparing the potential biosimilar PF-05280014 with trastuzumab in healthy volunteers ( REFLECTIONS B327-01).